Affiliation:
1. Jecure Therapeutics
2. National Jewish Health
3. Mayo Clinic
4. University of California San Diego
Abstract
Abstract
The NLRP3 inflammasome is an intracellular, multiprotein complex that promotes the auto-catalytic activation of caspase-1 and the subsequent maturation and secretion of the pro-inflammatory cytokines, IL-1β and IL-18. Persistent activation of the NLRP3 inflammasome has been implicated in the pathophysiology of a number of inflammatory and autoimmune diseases, including neuroinflammation, cardiovascular disease, non-alcoholic steatohepatitis, lupus nephritis and severe asthma. Here we describe the preclinical profile of JT002, a novel small molecule inhibitor of the NLRP3 inflammasome. JT002 potently reduced NLRP3-dependent proinflammatory cytokine production across a number of cellular assays and prevented pyroptosis, an inflammatory form of cell death triggered by active caspase-1. JT002 demonstrated in vivo target engagement at therapeutically relevant concentrations when orally dosed in mice and prevented body weight loss and improved inflammatory and fibrotic endpoints in a model of Muckle-Wells syndrome (MWS). In two distinct models of neutrophilic airway inflammation, JT002 treatment significantly reduced airway hyperresponsiveness and airway neutrophilia. These results provide a rationale for the therapeutic targeting of the NLRP3 inflammasome in severe asthma and point to the use of JT002 in a variety of inflammatory disorders.
Publisher
Research Square Platform LLC
Reference56 articles.
1. The inflammasomes;Schroder K;Cell,2010
2. Inflammasomes: mechanism of action, role in disease, and therapeutics;Guo H;Nat Med,2015
3. Mechanisms and functions of inflammasomes;Lamkanfi M;Cell,2014
4. Liu, X. & Lieberman, J. in Advances in Immunology Vol. 135 (ed Frederick W. Alt) 81–117 (Academic Press, 2017).
5. Release of interleukin-1alpha or interleukin-1beta depends on mechanism of cell death;England H;J Biol Chem,2014